Carisma Therapeutics Inc. announced the voluntary delisting of its common stock from Nasdaq, effective December 10, 2025, following a suspension due to noncompliance with Nasdaq L ...
Shares of Carisma Therapeutics Inc. (CARM) have been struggling lately and have lost 12.1% over the past week. However, a hammer chart pattern was formed in its last trading session, which could mean ...
Carisma Therapeutics Inc. (CARM) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings ...
Board of Directors has approved and the Company intends to proceed with the voluntary delisting of its common stock ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback